Alnylam Pharmaceuticals vs Royalty Pharma
ALNY and RPRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALNY and RPRX compare
Royalty Pharma is the larger company, worth 1.9 times as much as Alnylam Pharmaceuticals ($39.5B against $21.0B).
On earnings, Alnylam Pharmaceuticals is cheaper: it trades at 8.1× trailing earnings, against 39.0× for Royalty Pharma.
Alnylam Pharmaceuticals grew revenue faster over the last twelve months (56.2% versus 10.0% for Royalty Pharma).
Alnylam Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 52.8% compared with 32.1% at Royalty Pharma.
Royalty Pharma pays a dividend yielding 1.4%; Alnylam Pharmaceuticals does not pay one.
Alnylam Pharmaceuticals scores higher on the StockData Score (10 against 8 for Royalty Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALNY | RPRX |
|---|---|---|
| Size and price | ||
| Market cap | $21.0B | $39.5B |
| Share price | $156.50 | $68.68 |
| Change, 1 year | −65.2% | 75.4% |
| Change, 5 years | −17.0% | 64.0% |
| Beta (5Y) | 0.92 | 0.04 |
| Employees | 2,500 | 100 |
| StockData Score | ||
| Total score | 10 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 2 |
| Dividend score | 0 | 2 (better) |
| Valuation | ||
| P/E | 8.1× (better) | 39.0× |
| P/S | 4.2× (better) | 15.6× |
| P/B | 5.8× | – |
| EV/EBITDA | 16.8× (better) | 33.5× |
| P/FCF | 26.0× | – |
| PEG | – | 0.24 |
| FCF yield | 3.8% | – |
| Fair value | $296.91 | $45.76 |
| Margin of safety | 47.3% (better) | −50.1% |
| Growth | ||
| Revenue growth (TTM) | 56.2% (better) | 10.0% |
| Revenue growth, 5Y average | 49.8% (better) | 2.3% |
| Net income growth (TTM) | 2137% (better) | −20.4% |
| EPS growth (TTM) | 2308% (better) | −19.3% |
| EPS growth, 5Y average | – | 6.2% |
| Profitability | ||
| Gross margin | 77.4% | – |
| Operating margin | 19.5% | 59.6% (better) |
| Net margin | 52.8% (better) | 32.1% |
| FCF margin | 16.1% | – |
| Return on equity | 127% | – |
| Financial health | ||
| Net debt / EBITDA | – | 5.37 |
| Interest coverage | 3.2× | 4.2× (better) |
| Current ratio | 2.48 | 2.80 (better) |
| Altman Z-score | 3.62 (better) | 2.98 |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 1.4% |
| Buyback yield | – | 0.81% |
| Shareholder yield | 0.00% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 99.7% | 63.8% |
| Held by insiders | 0.49% | 22.6% |
| Insider net buying, 12 months | −$26.3M (better) | −$82.2M |
| Superinvestors holding | – | 2 |
| Short interest, % of float | 4.1% | 2.9% |
Go deeper
- ALNY stock overview
- ALNY income statement
- ALNY valuation and score
- RPRX stock overview
- RPRX income statement
- RPRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.